{
    "ticker": "ALNY",
    "name": "Alnylam Pharmaceuticals, Inc.",
    "description": "Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics based on RNA interference (RNAi) technology. Founded in 2002, Alnylam is pioneering a new class of medicines that can selectively silence genes associated with disease, which has the potential to transform the treatment of genetic disorders. The company has made significant strides in addressing rare diseases, particularly in areas such as hereditary ATTR amyloidosis and acute hepatic porphyria, with its lead product, ONPATTRO (patisiran), receiving FDA approval in 2018. Alnylam's expanding pipeline includes multiple investigational therapies targeting a variety of diseases, including neurological conditions and other genetic disorders. The company is committed to scientific excellence and innovation, working with a range of partners to bring RNAi therapeutics to patients worldwide. Alnylam aims to improve patient outcomes and quality of life by advancing the understanding and application of RNAi in medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2002",
    "website": "https://www.alnylam.com",
    "ceo": "Yvonne Greenstreet",
    "social_media": {
        "twitter": "https://twitter.com/Alnylam",
        "linkedin": "https://www.linkedin.com/company/alnylam-pharmaceuticals/"
    },
    "investor_relations": "https://investors.alnylam.com",
    "key_executives": [
        {
            "name": "Yvonne Greenstreet",
            "position": "CEO"
        },
        {
            "name": "Michael McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "RNAi Therapeutics",
            "products": [
                "ONPATTRO (patisiran)",
                "GIVLAIRI (givosiran)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alnylam Pharmaceuticals, Inc. | Pioneering RNAi Therapeutics",
        "meta_description": "Explore Alnylam Pharmaceuticals, a leader in RNA interference technology. Discover innovative therapeutics for genetic disorders and their commitment to patient care.",
        "keywords": [
            "Alnylam",
            "RNAi",
            "Biotechnology",
            "Pharmaceuticals",
            "Genetic Disorders",
            "ONPATTRO"
        ]
    },
    "faq": [
        {
            "question": "What is Alnylam Pharmaceuticals known for?",
            "answer": "Alnylam Pharmaceuticals is known for developing RNA interference (RNAi) therapeutics for genetic diseases."
        },
        {
            "question": "Who is the CEO of Alnylam?",
            "answer": "Yvonne Greenstreet is the CEO of Alnylam Pharmaceuticals."
        },
        {
            "question": "Where is Alnylam headquartered?",
            "answer": "Alnylam is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Alnylam's main products?",
            "answer": "Alnylam's main products include ONPATTRO (patisiran) and GIVLAIRI (givosiran)."
        },
        {
            "question": "When was Alnylam founded?",
            "answer": "Alnylam was founded in 2002."
        }
    ],
    "competitors": [
        "VRTX",
        "REGN",
        "SNY",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}